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ABSTRACT
Objective: To investigate the hearing prognosis of idiopathic sudden sensorineural hearing loss
(SSNHL) treated with different initial therapies.
Methods: Subjects consisted of patients diagnosed with idiopathic SSNHL within 7 days from onset
and showing severe hearing loss (60dB), who were registered in a Japanese multicenter database
between April 2014 and March 2016. Subjects were divided into four groups according to initial ther-
apy: (1) steroids, (2) steroidsþ Prostaglandins (PGs), (3) intratympanic steroids (ITS), and (4) no steroids.
Hearing outcomes were compared among the groups.
Results: In total, 1305 patients were enrolled. The final hearing level and hearing gain of patients
treated with steroidsþ PGs were significantly higher than those of patients treated with steroids alone
or no steroids. The ratio of good prognosis (complete recovery or marked improvement) in patients
treated with steroidsþ PGs was higher than that in patients treated with steroids alone or no steroids.
There was no difference in the prognosis of patients treated with steroids alone or no steroids.
Conclusion: A large number of patients with idiopathic SSNHL were registered in a multicenter data-
base. PG use in combination with steroid administration was associated with a good hearing prognosis
in patients with severe hearing loss.
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Introduction
Idiopathic sudden sensorineural hearing loss (SSNHL) is a
sensorineural hearing dysfunction of unknown etiology
characterized by the sudden onset and mostly unilateral
hearing loss. The latest epidemiological survey of hospitals
and clinics in Japan revealed that the incidence of idiopathic
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SSNHL was 60.9 per 100,000 population [1]. Little is known
about the pathogenesis of idiopathic SSNHL, but several
treatments have been proposed that cover the possible
underlying mechanisms of disease, such as viral infection,
intracochlear membrane rupture, and vascular compromise
[2,3]. As corticosteroids are known to be efficacious with
regard to the inner ear in cases with hearing loss of viral,
vascular, autoimmune, endolymphatic hydrops, and other
etiologies [4,5], systemic and/or intratympanic corticoste-
roids have been widely used for the treatment of idiopathic
SSNHL. However, the value of corticosteroid treatment for
idiopathic SSNHL remains unclear due to related studies
being of low methodological quality or based on small study
populations [6–8]. Prostaglandins (PGs) are vasoactive
agents that have also been used in SSNHL to enhance coch-
lear blood flow [9–11]. Although PGs have shown benefits
as vasodilators and inhibitors of platelet aggregation, the
value of PG treatment for idiopathic SSNHL is also unclear
because of the high risk of bias and small sample sizes [12].
Five single-year nationwide surveys of idiopathic SSNHL
have been conducted by the Research Committees of
Ministry of Health and Welfare in Japan. As part of these
surveys, a multicenter database was constructed, and large
numbers of patients with idiopathic SSNHL (N¼ 3419) have
been registered. In this study, we investigated the effects of
initial therapy on hearing prognosis in idiopathic SSNHL
based on an analysis of this survey data.
Material and methods
The subjects for this analysis were patients registered in the
multicenter database (involving 30 university hospitals and
medical centers) between April 2014 and March 2016.
Information regarding the patients’ sex, age, date of birth,
days from onset to visit, the incidence of vertigo/dizziness,
the incidence of diabetes mellitus, the use of systemic ste-
roids, PGs, and intratympanic steroid (ITS) injections, and
initial and final audiograms were obtained. Idiopathic
SSNHL was defined according to the criteria established by
the Sudden Deafness Research Committee of the Ministry of
Health and Welfare, Japan (Table 1). From the audiogram
data, the grade of the initial audiogram (Table 2) and the
recovery rate (Table 3), as defined by the Ministry of Health
and Welfare in Japan, were obtained.
To compare the prognosis for hearing outcome according
to initial treatment, we divided the patients into four groups:
(1) patients who were administered systemic corticosteroids
as initial therapy (steroids group), (2) patients who were
administered systemic corticosteroids and PGs as initial
therapy (steroidsþPGs group), (3) patients who were
administered ITS as initial therapy without systemic cortico-
steroid administration (ITS group), and (4) patients who
were not administered corticosteroids, ITS, or PGs (no ste-
roids group). Inclusion criteria consisted of a diagnosis of
idiopathic SSNHL within 7 days from onset and severe hear-
ing loss (Grade 3 or Grade 4). We excluded patients who
received ITS therapy as salvage therapy, so that 89 patients
from the steroids group and 73 patients from the
steroidsþPGs group were excluded from this study. We
also excluded patients whose data were incomplete.
The study protocol was approved by the ethics review
committees of Ehime University and other participating
institutional ethical committees.
Pearson’s chi-squared test was used to analyze the prog-
nosis for hearing. Other analyses were performed using the
t-test. All analyses were performed using JMP version 12.0.1
(SAS Institute Inc., Cary, NC).
Results
A total of 1305 patients were enrolled in this study. The ste-
roids group included 795 patients, the steroidsþPGs group
included 375 patients, the ITS group included 70 patients,
and the no steroids group included 65 patients. The clinical
characteristics of the four groups are summarized in
Table 4. There were no significant differences in gender,
affected side, incidence of vertigo/dizziness, days from onset
to visit, or initial hearing level among the groups. The
steroidsþPGs group was younger than the other groups
(p< .05 vs. steroids group, p< .01 vs. ITS and no steroids
groups), and the steroids group was younger than the ITS
and no steroids groups (p< .05). The incidences of diabetes
mellitus in the ITS and no steroids groups were higher than
those in the other groups (p< .01).
Table 1. Criteria for the diagnosis of idiopathic SSNHL.
Main symptoms
Sudden onset
Sensorineural hearing loss, usually severe
Unknown etiology
For reference
Hearing loss (hearing loss of 30 dB or more over three consecutive
frequencies)
Sudden onset of hearing loss, but may progressively deteriorate over 72 h
No history of recurrent episodes
Unilateral hearing loss, but may be bilateral at onset
May be accompanied by tinnitus
May be accompanied by vertigo, nausea, and/or vomiting, without recurrent
episodes
No cranial nerve symptoms other than from the cranial nerve VIII
Definite diagnosis; all of the above main symptoms are present
Table 2. Criteria for the grading of hearing loss in idio-
pathic SSNHL.
Grade Criteria
1 PTA <40 dB
2 40 dB PTA <60 dB
3 60 dB PTA <90 dB
4 90 dB PTA
PTA: arithmetic mean of five frequencies (250, 500,
1000, 2000, and 4000 Hz).
Table 3. Hearing improvement criteria for idiopathic SSNHL as defined by the
Ministry of Health and Welfare in Japan.
Hearing improvement status Criteria
Complete recovery All five frequencies of the final audiogram are
20 dB or less, or improvement to the same
degree of hearing in the unaffected side
Marked improvement PTA improvement 30 dB
Slight improvement 10 dB PTA improvement <30 dB
No change PTA improvement <10 dB
PTA: arithmetic mean of five frequencies (250, 500, 1000, 2000, and 4000 Hz).
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The hearing prognoses for the four groups are shown
in Table 5. Final hearing level was 52.7 ± 29.1 dB in the ste-
roids group, 47.0 ± 27.7 dB in the steroidsþPGs groups,
48.7 ± 25.9 dB in the ITS group, and 57.2 ± 29.5 dB in the no
steroids group. The final hearing level of the steroidsþPGs
group was better than those in the steroids and no steroids
groups (p< .01). Hearing gain was 33.0 ± 23.4 dB in the ste-
roids group, 37.8 ± 23.0 dB in the steroidsþPGs group,
35.7 ± 20.2 dB in the ITS group, and 27.7 ± 20.4 dB in the no
steroids group. The hearing gain in the steroidsþPGs group
was again higher than those in the steroids and no steroids
groups (p< .01), and that in the ITS group was higher than
that in the no steroids group (p< .05). The ratio of good
prognosis (complete recovery or marked improvement) was
higher in the steroidsþPGs group than in the steroids and
no steroids groups (p< .01).
Discussion
Evaluation of therapy for idiopathic SSNHL is complicated
as there is a certain rate of spontaneous improvement,
which ranges between 35% and 65% [13,14]. A meta-ana-
lysis of various medical treatments, including corticosteroids,
showed a slight but not statistically significant improvement
with medical therapy compared with a placebo [15]. As
there is no high-quality evidence, initial systemic corticoster-
oid therapy is regarded as an option in the American
Clinical Practice Guideline for idiopathic SSNHL [16]. In
this survey, hearing gain in the steroids, ITS, and no steroids
groups was 33.0 ± 23.4 dB, 35.7 ± 20.2 dB, and 27.7 ± 20.4 dB,
respectively. The ratio of good prognosis in the steroids,
ITS, and no steroids groups was 60.3%, 62.8%, and
53.8%, respectively. The effect of systemic or intratympanic
corticosteroid therapy was slightly better than the effect
observed in patients not administered corticosteroids, but
this difference was not significant. Lee et al. [17] reported
that steroid dose reduction increased the possibility of no
recovery. Although the efficacy of corticosteroid therapy for
idiopathic SSNHL has been questioned, systemic or intra-
tympanic corticosteroid therapy might still be considered.
In this survey, the use of PGs in combination with cor-
ticosteroid administration was associated with good hearing
prognosis. PGs have numerous biological actions, such as
the inhibition of receptor-mediated stimulation of platelet
aggregation, cytoprotection, and vasodilation [18]. Ogawa
et al. [10] reported that there were no significant differences
between treatment with steroidþPGE1 and steroid only,
although hearing improvement at high frequencies was sig-
nificantly better in the steroidþPGE1 group than in the
steroid only group. Ahn et al. [19] reported that lipo-PGE1
may have beneficial effects in the treatment of idiopathic
SSNHL in patients with type 2 diabetes. On the other hand,
a clinical trial in Japan using a single drug did not show any
differences between the PGE1 only and steroid only groups
[20]. In this study, we investigated initial treatment efficacy
in idiopathic SSNHL patients with severe hearing loss, and
found that the use of PGs appeared to afford better hearing
outcomes. We also performed an analysis of the type of
patients for whom steroidþPGs had been more effective. In
this further analysis, we compared the hearing outcome
between the steroids group and steroidsþPGs group strati-
fied by gender, side of hearing loss, age group (under 65 or
65 and over), days from onset of hearing loss (under 4 days
or 4–7 days), initial grade of hearing loss (3 or 4), present-
ing symptoms (tinnitus, vertigo), and presenting systemic
comorbidities (diabetes mellitus, hyperlipidemia, heart dis-
ease, brain infraction). The results revealed that
steroidsþPGs were more effective in patients who were
female, aged 65 and over, treated under 4 days from the
onset of hearing loss, and presenting with vertigo, based on
our definition of effective as a calculated odds ratio of over
1.50 (see Supplemental Table 1).
There were various biases in this survey. This study was
retrospective, and we excluded patients who had received
ITS for salvage therapy in order to ascertain the effectiveness
of the initial treatment for idiopathic SSNHL. In fact, 89
patients from the steroids group (accounting for 10.1% of
the patients receiving systemic steroids without PGs as the
initial therapy) and 73 patients from the steroidsþPGs
group (16.3% of the patients receiving systemic
steroidsþPGs as the initial therapy) were excluded for that
reason. Therefore, there is a possibility that the hearing
prognoses for the steroids and steroidsþPGs groups might
be better than the actual results. However, as the hearing
outcome was better in the steroidsþPGs group than in the
steroids group, the effectiveness of PGs combined with ster-
oid appears certain. In addition, age and the frequency of
diabetes were higher in the ITS and no steroids groups. In
this study, we did not find any relationship between hearing
outcome and patient characteristics, including age and dia-
betes. Although further prospective randomized clinical
Table 4. The clinical characteristics of patients.
Steroids
group
Steroidsþ PGs
group
ITS
group
No steroids
group
No. of patients 795 375 70 65
Gender (male/female) 435/360 183/192 42/28 31/34
Affected side (right/left) 388/407 175/200 40/30 30/35
Age (years)
Mean ± SEM 55.4 ± 17.7a 53.3 ± 17.0a 59.9 ± 14.5 63.0 ± 15.9
Incidence of vertigo/dizziness 38.6% 37.1% 27.9% 39.4%
Incidence of diabetes 17.5% 18.8% 54.4%b 43.8%b
Days from onset to visit 2.8 ± 1.9 2.6 ± 1.8 3.1 ± 2.0 2.7 ± 2.0
Initial hearing level
Mean ± SEM (dB) 85.6 ± 15.7 84.8 ± 15.3 84.4 ± 15.1 84.8 ± 17.6
(Grade 3/Grade 4) 488/307 241/134 47/23 38/27
ap< .05 vs. ITS group and p< .01 vs. no steroids group.
bp< .01 vs. steroids group and steroidsþ PGs group.
Table 5. Hearing outcome of patients.
Steroids
group
Steroidsþ PGs
group ITS group
No steroids
group
Final hearing level
Mean ± SEM (dB) 52.7 ± 29.1 47.0 ± 27.7a 48.7 ± 25.9 57.2 ± 29.5
Hearing gain
Mean ± SEM (dB) 33.0 ± 23.4 37.8 ± 23.0a 35.7 ± 20.2b 27.7 ± 20.4
Ratio of good prognosis
(Complete recoveryþ
marked improvement)
479 (60.3%) 263 (70.1%)c 44 (62.8%) 35 (53.8%)
ap< .01 vs. steroids group and no steroids group.
bp< .05 vs. no steroids group.
cp< .01 vs. steroids group and no steroids group.
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studies are necessary to fully evaluate the usefulness of initial
therapies, we believe that the use of PGs in combination
with systemic corticosteroid therapy is associated with a
good hearing prognosis in patients with severe idiopathic
SSNHL.
Conclusions
A large number of patients with idiopathic SSNHL were reg-
istered in a multicenter database, and the relationship
between initial treatment type and hearing outcome was
analyzed. The effect of systemic or intratympanic cortico-
steroid therapy was slightly better than that of therapy with-
out corticosteroids, but the difference was not significant.
The use of PGs in combination with steroid administration
was associated with good hearing prognosis in idiopathic
SSNHL patients with severe hearing loss.
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